CBP30, a selective CBP/p300 bromodomain inhibitor, suppresses human Th17 responses

Th17 responses are critical to a variety of human autoimmune diseases, and therapeutic targeting with monoclonal antibodies against IL-17 and IL-23 has shown considerable promise. Here, we report data to support selective bromodomain blockade of the transcriptional coactivators CBP (CREB binding pro...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Proceedings of the National Academy of Sciences - PNAS 2015-08, Vol.112 (34), p.10768-10773
Hauptverfasser: Hammitzsch, Ariane, Tallant, Cynthia, Fedorov, Oleg, O’Mahony, Alison, Brennan, Paul E., Hay, Duncan A., Martinez, Fernando O., Al-Mossawi, M. Hussein, de Wit, Jelle, Vecellio, Matteo, Wells, Christopher, Wordsworth, Paul, Müller, Susanne, Knapp, Stefan, Bowness, Paul
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!